20 August 2024
Hogan Lovells advises Merck as it enters into definitive agreement to acquire CN201, an autoimmune treatment drug
Advising firms
Deal team
3 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Mahvesh Qureshi Lead | Hogan Lovells Cadwalader | Partner | Not stated | Washington, D.C. |
| Gabi Witt Lead | Hogan Lovells Cadwalader | Partner | Not stated | Washington, D.C. |
| Derrik Forshee Lead | Hogan Lovells Cadwalader | Partner | Not stated | Baltimore |
Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 700m (US$700 million)
- What the figure measures
- Total transaction value
- Client
- MerckBuy-side
- Counterparties
- Curon Biopharmaceutical Limited (Sell-side)